Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2019 09:14 ET | Source: Genmab A/S

Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.

Company Announcement Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judgment Copenhagen, Denmark; January 26, 2019 – Genmab...
January 22, 2019 10:57 ET | Source: Genmab A/S

Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma

Company Announcement First part of regulatory package submitted to the U.S. FDA for label expansion of daratumumab in combination with lenalidomide and dexamethasone for patients with newly...
January 22, 2019 06:44 ET | Source: Genmab A/S

Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)

Company Announcement Net sales of DARZALEX in 2018 totaled USD 2,025 millionGenmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 22, 2019 – Genmab...
January 17, 2019 13:37 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish...
January 08, 2019 12:34 ET | Source: Genmab A/S

Genmab Achieves USD 75 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

Company Announcement Genmab to receive milestone payment of USD 75 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 2 billion in a calendar year Copenhagen,...
January 03, 2019 08:48 ET | Source: Genmab A/S

Genmab to Present at the 37th Annual J.P. Morgan Healthcare Conference

Media Release Copenhagen, Denmark, January 3, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 37th Annual J.P....
December 20, 2018 05:26 ET | Source: Genmab A/S

Genmab Announces European Commission Approval of DARZALEX® (daratumumab) Split Dosing Regimen

Media Release Split dosing regimen approved by European CommissionProvides healthcare professionals with option to split first DARZALEX infusion over two consecutive daysApproval supported by data...
December 13, 2018 20:58 ET | Source: Genmab A/S

Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan

Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed...
December 10, 2018 13:41 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab

Company Announcement Copenhagen, Denmark; December 10, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 80,380 restricted stock units to...
December 03, 2018 02:17 ET | Source: Genmab A/S

Genmab to Hold R&D Update and 2018 ASH Data Review Meeting

Media Release Event to be held today in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...